Cancer immunotherapy medication
Metadata
| Name | Cancer immunotherapy medication |
| Type | Disease or Syndrome |
| Group | Disease or Syndrome |
| Data Sources |
|
| Clinical Terminologies |
British National Formulary |
| Codelists | |
| Valid Event Data Range | 01/01/1999 - 01/07/2019 |
| Sex |
Female Male |
| Authors | Lai A. |
| Agreement Date | 1 Mar 2019 |
| Version (UUID) | 1 (Vkf6SPU4ig6A4ARJkYnP2r) |
Primary care
| prodcode | prodname | drugsubstance | bnfcode | strength |
|---|---|---|---|---|
| 25740 | Avastin 100mg/4ml solution for infusion vials (Roche Products Ltd) | Bevacizumab | 8010500 | 25mg/1ml |
| 27292 | Herceptin 150mg powder for concentrate for solution for infusion vials (Roche Products Ltd) | Trastuzumab | 8010500 | 150mg |
| 28490 | Rituximab 100mg/10ml solution for infusion vials | Rituximab | 08020300/10010301 | 10mg/1ml |
| 31076 | Trastuzumab 150mg powder for solution for infusion vials | Trastuzumab | 8010500 | 150mg |
| 31598 | MabCampath 30mg/3ml concentrate for solution for infusion ampoules (Schering Health Care Ltd) | Alemtuzumab | 0 | 10mg/1ml |
| 32712 | Erbitux 100mg/50ml solution for infusion vials (Merck Serono Ltd) | Cetuximab | 0 | 2mg/1ml |
| 33205 | Cetuximab 100mg/50ml solution for infusion vials | Cetuximab | 0 | 2mg/1ml |
| 36294 | Rituximab 500mg/50ml solution for infusion vials | Rituximab | 08020300/10010301 | 10mg/1ml |
| 38145 | Bevacizumab 100mg/4ml solution for infusion vials | Bevacizumab | 8010500 | 25mg/1ml |
| 38158 | Cetuximab 100mg/20ml solution for infusion vials | Cetuximab | 8010500 | 5mg/1ml |
| 39111 | Rituximab 10mg/ml concentrated intravenous infusion | Rituximab | 08020300/10010301 | 10mg/ml |
| 42273 | Alemtuzumab 30mg/1ml solution for infusion vials | Alemtuzumab | 8020300 | 30mg/1ml |
| 44004 | Denosumab 60mg/1ml solution for injection pre-filled syringes | Denosumab | 6060200 | 60mg/1ml |
| 44084 | Prolia 60mg/1ml solution for injection pre-filled syringes (Amgen Ltd) | Denosumab | 6060200 | 60mg/1ml |
| 45122 | Panitumumab 100mg/5ml solution for infusion vials | Panitumumab | 8010500 | 20mg/1ml |
| 47502 | MabThera 100mg/10ml concentrate for solution for infusion vials (Roche Products Ltd) | Rituximab | 08020300/10010301 | 10mg/1ml |
| 54058 | Denosumab 120mg/1.7ml solution for injection vials | Denosumab | 6060200 | 70mg/1ml |
| 55815 | MabCampath 30mg/1ml concentrate for solution for infusion vials (Genzyme Therapeutics Ltd) | Alemtuzumab | 8020300 | 30mg/1ml |
| 56041 | Ipilimumab 50mg/10ml solution for infusion vials | Ipilimumab | 8010500 | 5mg/1ml |
| 58018 | Xgeva 120mg/1.7ml solution for injection vials (Amgen Ltd) | Denosumab | 6060200 | 70mg/1ml |
| 58142 | Brentuximab vedotin 50mg powder for solution for infusion vials | Brentuximab vedotin | 8010500 | 50mg |
| 58819 | Herceptin 600mg/5ml solution for injection vials (Roche Products Ltd) | Trastuzumab | 8010500 | 120mg/1ml |
| 58862 | Ipilimumab 200mg/40ml solution for infusion vials | Ipilimumab | 8010500 | 5mg/1ml |
| 59276 | Erbitux 100mg/20ml solution for infusion vials (Merck Serono Ltd) | Cetuximab | 8010500 | 5mg/1ml |
| 61908 | Pertuzumab 420mg/14ml solution for infusion vials | Pertuzumab | 8010500 | 30mg/1ml |
| 66436 | Cetuximab 500mg/100ml solution for infusion vials | Cetuximab | 8010500 | 5mg/1ml |
| 69589 | Alemtuzumab 12mg/1.2ml solution for infusion vials | Alemtuzumab | 8020500 | 10mg/1ml |
| 70553 | Obinutuzumab 1g/40ml solution for infusion vials | Obinutuzumab | 8020500 | 25mg/1ml |
| 71157 | Nivolumab 100mg/10ml solution for infusion vials | Nivolumab | 8010500 | 10mg/1ml |
| 71269 | Pembrolizumab 100mg/4ml solution for infusion vials | Pembrolizumab | 8010500 | 25mg/1ml |
| 72094 | Truxima 500mg/50ml concentrate for solution for infusion vials (Napp Pharmaceuticals Ltd) | Rituximab | 08020300/10010301 | 10mg/1ml |
| 72422 | Avelumab 200mg/10ml solution for infusion vials | Avelumab | 8010500 | 20mg/1ml |
| 73083 | Lemtrada 12mg/1.2ml concentrate for solution for infusion vials (Genzyme Therapeutics Ltd) | Alemtuzumab | 8020500 | 10mg/1ml |
| 73295 | Trastuzumab 600mg/5ml solution for injection vials | Trastuzumab | 8010500 | 120mg/1ml |
| 73503 | Rixathon 100mg/10ml concentrate for solution for infusion vials (Sandoz Ltd) | Rituximab | 08020300/10010301 | 10mg/1ml |
| 74553 | Truxima 100mg/10ml concentrate for solution for infusion vials (Napp Pharmaceuticals Ltd) | Rituximab | 08020300/10010301 | 10mg/1ml |
Publications
-
Lai A. et al. Estimating excess mortality in people with cancer and multimorbidity in the COVID-19 emergency. DOI: 10.1101/2020.05.27.20083287
-
Banerjee A. et al. Estimating excess 1-year mortality associated with the COVID-19 pandemic according to underlying conditions and age: a population-based cohort study. The Lancet. DOI: 10.1016/S0140-6736(20)30854-0